Kenvue Inc. (NYSE:KVUE) Plans Quarterly Dividend of $0.20

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, April 25th, Zacks reports. Stockholders of record on Wednesday, May 8th will be given a dividend of 0.20 per share on Wednesday, May 22nd. This represents a $0.80 annualized dividend and a dividend yield of 4.17%. The ex-dividend date of this dividend is Tuesday, May 7th.

Kenvue has a payout ratio of 65.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.25 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 64.0%.

Kenvue Stock Up 0.4 %

Shares of Kenvue stock opened at $19.20 on Monday. Kenvue has a 1 year low of $17.82 and a 1 year high of $27.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The business has a 50 day moving average price of $19.82 and a 200 day moving average price of $20.12.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The company had revenue of $3.67 billion for the quarter, compared to analyst estimates of $3.78 billion. The company’s quarterly revenue was down 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Kenvue will post 1.15 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on KVUE shares. JPMorgan Chase & Co. reduced their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 price target on the stock. Royal Bank of Canada dropped their price target on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, William Blair initiated coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.